

Molecular signature associated with plasticity of bone marrow cell under persistent liver damage by self-organizing-map-based gene expression[☆]

Kaoru Omori^{a,*}, Shuji Terai^{a,*}, Tsuyoshi Ishikawa^a, Kouji Aoyama^a, Isao Sakaida^a, Hiroshi Nishina^b, Koh Shinoda^c, Shunji Uchimura^d, Yoshihiko Hamamoto^d, Kiwamu Okita^a

^aDepartment of Molecular Science and Applied Medicine (Gastroenterology and Hepatology), Yamaguchi University School of Medicine, Minami Kogushi 1-1-1, Ube, Yamaguchi 755 8505, Japan

^bDepartment of Physiological Chemistry, Graduate School of Pharmaceutical Science, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113 0033, Japan

^cDepartment of Neuroanatomy and Neuroscience, Yamaguchi University School of Medicine, Minami Kogushi 1-1-1, Ube, Yamaguchi 755 8505, Japan

^dDepartment of Computer Science and Systems Engineering, Faculty of Engineering, Yamaguchi University, Tokiwadai 2-16-1, Ube, Yamaguchi 755 8505, Japan

Received 22 April 2004; revised 3 September 2004; accepted 23 September 2004

Available online 2 November 2004

Edited by Gianni Cesareni

Abstract The mechanism that regulates the plasticity of bone marrow cells (BMCs) into hepatocytes is poorly understood. We developed a green fluorescent protein/carbon tetrachloride model to find that BMC transplantation recovered liver damage. Serum albumin level and liver fibrosis were recovered by BMC transplantation. To understand the mechanism, we used DNA-chip technology to profile the change of transient gene expression before and after BMC transplantation. On the basis of gene expression with self-organizing map using specific equation, genes were classified into 153 clusters. The information is useful to understand the dramatic gene activation during the process of the plasticity of BMC.

© 2004 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Keywords: Bone marrow cell; Plasticity; Regenerative Medicine; Gene expression; Microarray analysis; Self-organizing map; Liver regeneration

1. Introduction

Recently, several groups have reported the possible plasticity of bone marrow cells (BMC) to differentiate into a variety of non-hematopoietic cell lineages [1,2]. Ever since, the differentiation of BMC into hepatocytes in human was documented following a bone marrow transplantation from a man to a woman [3]. The mechanism of the plasticity of BMC was discussed whether that was occurred with cell fusion, nuclear reprogramming [4–6] or trans-differentiation [7,8]. We think both cell fusion and trans-differentiation might be important to understand the mechanism of BMC plasticity. On the other hand, in cardiovascular medicine, clinical research has been conducted to evaluate the use of BMCs in regenerating the myocardium and vessels, and some positive results have been obtained [9,10]. These findings suggest the usefulness of BMCs as the source of cells in developing the next-generation of treatment for liver regeneration [11]. We first tried to understand how we could use BMC to repair damaged liver. We have developed a model [named as a green fluorescent protein/carbon tetrachloride (GFP/CCl₄)] to evaluate the usefulness of BMC transplantation for damaged liver [12,13]. In this model, 0.5 ml/kg of carbon tetrachloride (CCl₄) is administered twice weekly to induce liver cirrhosis and then GFP-positive BMCs are transplanted through the causal vein [14]. Under continuous liver injury, immunostaining using anti-GFP antibodies [15] showed that GFP-positive BMCs migrated into the marginal area of the hepatic lobule starting from day 1 after BMC transplantation, and with time, while forming a hepatic cord towards the central vein, the distribution of GFP-positive BMCs expands [12,16]. Also, using Liv2, a hepatoblast-specific antibody that we developed [17], it has been shown that BMCs first trans-differentiate into Liv2-positive hepatoblasts and then differentiated into albumin-positive hepatocytes. Furthermore, the level of serum albumin significantly increases with time in recipient mice. Liver fibrosis induced by CCl₄ injection was recovered by BMC transplantation [18]. These findings suggest that this GFP/CCl₄ model can be used

[☆] Grant Support: This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Nos. 13470121, 13770262, 15790348, 16390211 and 16590597) and for translational research from the Ministry of Health, Labor and Welfare (H-trans-5).

* Corresponding author. Fax: +81-836-222-240.
E-mail address: terais@yamaguchi-u.ac.jp (S. Terai).

Abbreviations: BMC, bone marrow cell; SOM, self-organizing map; CCl₄, carbon tetrachloride; EGFP, enhanced GFP; GFP, green fluorescent protein; RT, reverse transcriptase; HNF4- α , hepatocyte nuclear factor 4 alpha; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; FAH, fumarylacetoacetate hydrolase; TNFR, tumor necrosis factor receptor; FGF, fibroblast growth factor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; NumbL, Numblike; HOX, homeobox; GPI, glucose-6-phosphatase isomerase

to understand the process of plasticity of BMCs under persistent liver damage condition. It is important to understand what had happened in GFP/CCl₄ model after BMC transplantation in mRNA level. DNA chips are recently developed tools used in genetic analyses [19]. While it is possible to obtain genetic data using DNA chips, the vast amount of information collected makes it difficult to precisely interpret the factors involved in the gene expression. Therefore, in the present study, patterns of global gene expression at different

times were compared between mice with BMC transplantation and those without. Self-organizing map (SOM) is a statistical technique that has been recently used in analyzing microarray data and, via this method, it is possible to visualize a vast amount of complicated and multidimensional data [20]. In this analysis, we made a specific equation to extract genes with expressions that altered in relation to BMC transplantation. Here, we present the results obtained from this study.




Fig. 1. Defined equation in this analysis. (↓) Arrow indicates CCl₄ injection twice a week in GFP/CCl₄ model. We analyzed gene expression in each time point (2 days, 1 week, 2 weeks, 3 weeks, and 4 weeks). $y_i(t)$ showed the gene expression level of the liver after BMC transplantation. $x_i(t)$ showed the gene expression level of the liver CCl₄ alone injection group. We define $f_i(t)$: $f_i(t) = \log_{10} y_i(t) / x_i(t)$. By using this, we succeeded in extracting the change of gene expression by BMC transplantation. We are interested in following the change of the values of $F_i(t) = f_i(t+1) - f_i(t)$ with the increase in t .

Table 1
Lists of primers for selected 13 genes

Cluster	Gene name (Accession No.)	Primer – forward (5'–3') Primer – reverse (5'–3')	Target	Tm
86	c-kit (NM02099)	TCCAACGATGTGGGCAAGAG AATGAGCAGCGCGTGAA	90	55
86	FGP6 (M92415)	CATGGTCTATACCGGCCACA GGCTGCTGACATGAAACCAAAG	88	63
125	MMP2 (NM008610)	CCCTGATGTCCAGCAAGTAGATG ATTCCAGGAGTCTGCGATGAG	148	62
125	MMP9 (NM013599)	ACGACATAGACGGCATCCAGTA TCGGCTGTGGTTCAGTTGTG	90	53
92	TIMP2 (NM011594)	ACACGCTTAGCATCACCCAGA TGTGACCCAGTCCATCCAGAG	137	63
13	HGF (NM010427)	CCCAAACATCCGAGTTGGCTAC TTCCCATTTGCCACGATAACA	84	63
1	NumbL (NM010950)	TATGCAGCCTCCGTTTGTG GCGTTGGCTACCATCTGTGAA	102	62
1	HOXD3 (NM010468)	CCATAAATCAGCCGCAAGGA GGATGGGTCGAGGACTTACCTTAG	112	63
152	GPI (NM008155)	TGGACGGCAAAGATGTGATG CGATGTTGATGATGTCGCTGA	129	63
152	VEGF (NM009505)	ATGCGGATCAAACGTCACCA CCGCTCTGAACAAGGCTCAC	129	63
136	TNFR1 (NM011609)	CTGCTCTACGAATCACTCTGCTC ACAGCATACAGAATCGCAAGGTC	113	62
151	HNF4 (NM008261)	CCAAAGTACATCCCGGCCTTC CTAGGAGCAGCAGCTCCTTAAAC	132	62
151	FGF2 (NM008006)	GGCTGCTGGCTTCTAAGTGTG ACTGCCAGTTCGTTTCAGTG	129	62

2. Materials and methods

2.1. Experimental protocol (GFP/CCl₄ model)

We developed a new in vivo model in which we could monitor the plasticity of BMCs into hepatocytes [12,16]. The mouse line C57BL/6 Tg14 (act-EGFP) OsbY01 was a kind gift from Dr. Masaru Okabe (Genome Research Center, Osaka University, Osaka, Japan) [14]. C57BL/6 female mice were purchased from Japan SLC (Shizuoka, Japan). We injected 0.5 ml/kg body weight of CCl₄ into C57BL/6 mice at 6 weeks of age via the peritoneum twice a week for 4 weeks to induce persistent liver damage. At this time, the condition of recipient mice was liver cirrhosis. One day after 4 weeks of CCl₄ injection, 1×10^5 GFP-positive BMCs were injected slowly using a 31 G needle and Hamilton syringe via the tail vein. The mice that were injected with CCl₄ only were used as the control group. After BMC transplantation, the same dose of CCl₄ was injected twice a week. Individual mice were killed at 18 h after initial CCl₄ injection (2 days after BMC transplantation) and once a week after BMC transplantation for 4 weeks. All processes including surgical steps confirmed to the guidance of Yamaguchi University for animal and recombinant DNA experiments.

2.2. RNA preparation and microarray analysis

In both the BMC transplantation and control groups, the liver was excised 2 days and 1, 2, 3, and 4 weeks after transplantation. The mice were killed by cervical dislocation. The whole liver was removed and immediately frozen in liquid nitrogen. Liver samples were pooled at least two from whole liver of both mice groups (BMC transplantation and control CCl₄ damage at each points). Total RNA was isolated from pooled liver samples using an Atlas Glass Total RNA Isolation Kit (Clontech, Palo Alto, CA) [21]. Single strands of cDNA were synthesized using the primer mix, dNTP, aminoacyl dUTP, and MMLV-RT using an Atlas Glass Fluorescent Labeling Kit (Clontech). The synthesized cDNA probes were coupled to monoreactive Cy3 for fluorescent labeling. Probes were prepared in the same manner for the control group (no BMC transplantation) and BMC transplantation group at the same time. The DNA microarray analysis was conducted using an Atlas Glass Mouse 1.0K Microarray System (Clontech) [22]. The above-mentioned cDNA probes were hybridized to a DNA chip composed of about 1100 DNA fragments by incubating the chip overnight at 50 °C with the probe. After incubation, the chip was washed using GlassHyb Wash Solution, RNase water and 20× SSC, rinsed with distilled water and then air dried. The signal intensity of each gene was measured using a fluorescent scanner (Axon Instruments, CA). The spot intensity of expression of each gene was assessed using the ArrayGauge System (Fuji Film, Tokyo, Japan). The raw data of the spot intensity were used for SOM analysis (All raw data of microarray are available at <http://liver-project.med.yamaguchi-u.ac.jp/research/>). We performed several analyses to obtain representative data.

2.3. SOM analysis for microarray

The microarray analysis showed that, of the 1100 genes on the DNA chips, although the expression of some genes was too small for further analysis, the expression data recorded of the remaining 1018 genes were sufficient for SOM data analysis. At each of five sampling times, i.e., 2 days and each week for 4 weeks, expression levels of 1018 genes for both control CCl₄ damage and BMC transplantation group were measured, respectively. To extract the genes that are differentially expressed before and after BMC transplantation, we defined the following equation (Fig. 1):

$$f_i(t) = \log_{10} \frac{y_i(t)}{x_i(t)}, \quad t = 1, 2, 3, 4, 5, \quad i = 1, 2, \dots, 1018 \quad (1)$$

where $x_i(t)$ is the expression level of the control CCl₄ alone sample (CCl₄ alone without BMC transplantation) and $y_i(t)$ is the expression level of BMC transplantation sample for gene i (1, 2, ..., 1018) at sampling point t , respectively. The term $f_i(t)$ represents the expression level of GFP/CCl₄ group normalized by the control group. If $y_i(t) = x_i(t)$, at that the value of $f_i(t)$, i.e., $\log_{10} 1$, was zero. By using this, we succeeded in extracting the change of gene expression by BMC transplantation. Point t shows time. $t = 2d, 1w, 2w, 3w$, and $4w$ showed 1, 2, 3, 4, and 5, respectively. To extract the change of gene expression with time, we followed the change of the values of

$f_i(t+1) - f_i(t)$ with the increase in t . Using $f_i(t)$, we defined the 4-dimensional vector $F_i = [F_i(1), F_i(2), F_i(3), F_i(4)]^T$ for gene i , where

$$F_i(1) = f_i(2) - f_i(1)$$

$$F_i(2) = f_i(3) - f_i(2)$$

$$F_i(3) = f_i(4) - f_i(3)$$

$$F_i(4) = f_i(5) - f_i(4)$$

All genes were described and then used as input patterns for SOM analysis. SOM was performed using the SOM toolbox in MATLAB (The Mathworks Inc., Natick, MA; and <http://www.cis.hut.fi/projects/somtoolbox/>).

Each element of these vectors [$F_i(i = 1, 2, 3, \dots, 1018)$] represents a chronological change of gene expression after BMC transplantation in GFP/CCl₄ model.

2.4. Reverse transcriptase (RT)-PCR analysis

Total RNA was isolated from the whole liver of both mice groups (BMC transplantation and control CCl₄ damage ($n = 2$, each group) using Isogen Total-RNA isolation kit (Nippon Gene Co., Ltd., Tokyo, Japan) at each of five sampling times, i.e., 2 days and each week for 4 weeks. These samples were obtained by independent experiments from microarray analysis. RT step was performed using SYBR RT-PCR kit (Takara Co., Tokyo, Japan).




Fig. 2. The 1018 genes analyzed using microarray were divided into 153 clusters and arranged in a 17 × 9 matrix (height × width) of 153 hexagons (all raw data of microarray are available at <http://liver-project.med.yamaguchi-u.ac.jp/research/>). The number of genes varied among the clusters. Clusters with similar elements were arranged close to each other in the matrix.

Two μl of cDNA solution (100 ng of initial RNA) was amplified in 20 μl of reaction mixture containing 5 pmol of forward and reverse primer. PCR was performed for a total of 45 cycles, each of 95 °C for 5 s and 60 °C for 20 s [23]. We selected 13 genes to further clarify the difference expression pattern of each gene. c-kit, fibroblast growth factor (FGF)-6, matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-2, Hepatocyte growth factor (HGF), Numblike (NumbL) and homeobox (HOX) - D3, Glucose-6-phosphatase isomerase (GPI), vascular endothelial growth factor (VEGF), tumor necrosis factor receptor (TNFR)-1, hepatocyte nuclear factor (HNF)-4 and FGF-2 were selected. The primer used in this study is shown in Table 1. The relative ratio of each gene expression was determined referring with the mean expression level of control house keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18 S ribosomal RNA expression.

2.5. SOM analysis compared between RT-PCR and microarray

To validate the results of SOM analysis depend on microarray, we compared SOM analysis between microarray and RT-PCR. We used the same equation and performed SOM analysis (Fig. 1) based on both the data of RT-PCR and microarray.




Fig. 3. The median value for gene expression for $F1$, $F2$, $F3$, and $F4$ in each cluster is presented as a bar chart. As a reference, in cluster 1, the median value in $F1$ and $F3$ was increased, while that in $F2$ and $F4$ was decreased.

3. Results

The 1018 genes that could be analyzed by the DNA chips were classified into 153 clusters by SOM (Fig. 2). Genes in the same cluster showed similar gene expression pattern during the process of BMC trans-differentiation. On the SOM matrix, clusters with similar vector F_i elements ($F1$ – $F4$) were arranged in close proximity to each other. Therefore, adjacent clusters on the matrix exhibited similar chronological changes in gene expression profiles during the process of plasticity of BMC into hepatocyte. Fig. 3 shows bar charts that represent the median value of gene expression for each cluster in $F1$, $F2$, $F3$, and $F4$. By analyzing each element ($F1$ – $F4$) of vector F_i , the clusters were color coded to aid visualization of the SOM data (Fig. 4). For example, in the $F1$ output, clusters 69, 70, and 86 containing upregulated genes in $F1$ were colored dark brown. On the other hand, clusters with downregulated genes in $F1$ were colored dark blue. The color bar on the right-hand side of the figure indicates the degree of gene expression from $F1$ to $F4$, and a value of 0 indicates that there was little transient change in gene expression between the BMC transplantation and control CCl_4 injection groups. The following clusters exhibited marked changes in transient gene expression: in $F1$, clusters 69, 70, 86, 92, 125, 140, 141, 142, and 143; in $F2$, clusters 13, 14, 15, 16, 17, 32, 33, and 34; in $F3$, clusters 1, 2, 18, and 137; and in $F4$, clusters 118, 119, 133, 134, 135, 136, 148, 149, 150, 151, 152, and 153. To validate the data of SOM analysis based on microarray analysis, we performed SOM




Fig. 4. The clusters were color-coded based on the median values for gene expression at the $F1$, $F2$, $F3$, and $F4$ time periods. The color bar on the right hand side indicates the values in each period; dark brown for upregulated and dark blue for downregulated. A value of 0 indicates that there was little chronological change in gene expression between the transplantation and control groups.

analysis based on the data of RT-PCR for selected 13 genes using the same equation (Figs. 5A and B). Table 2 shows the list of genes in each cluster.

4. Discussion

By using specific equation to extract change of gene expression after BMC transplantation, we found that there were dramatic changes for both gene expression and distribution of gene clusters after BMC transplantation in GFP/CCl₄ model (Figs. 3 and 4). 1018 genes were classified into 153 patterns of change of gene expression using SOM analysis. These results might show that many genes had important reciprocal roles during the process of differentiation of BMC into albumin positive hepatocyte. To validate the SOM analysis based on microarray analysis, we performed SOM analysis based on selected 13 gene expressions analyzed by RT-PCR independently. *c-kit*, *FGF6*, *MMP2*, *MMP9*, and *TIMP2* were selected from serious clusters at *F1* periods (clusters 86, 92, and 125). *HGF* was selected from *F2* periods (cluster 13). *NumbL* and *HOXD3* were selected from *F3* (cluster 1). *GPI*, *VEGF*, *TNFR1*, *HNF4*, and *FGF2* were selected from *F4* (clusters

136, 151, and 152). As shown in Fig. 5, we found the similar position of these selected genes. This means that the change of gene expression from microarray analysis is similar to that from RT-PCR analysis. These results showed the consistency of SOM analysis based on microarray using specific equation.

Cluster with color deeper than dark orange (69, 70, 125, 141, 142, and 143) showed the dramatic change in *F1* period (Fig. 4). The *c-kit* gene, which was present in cluster 86, encodes a stem cell factor receptor which is related with rat hepatic stem cell, oval cell, activation [24]. *FGF-6* was also extracted in cluster 86. *FGF* was known to have an important role of hepatocyte proliferation and liver development [25]. To focus on the change of *F1* to *F4* in cluster 86, we found that genes in cluster 86 were upregulated soon after BMC transplantation suggesting that the expression of these genes changes dynamically and might have an important role in the early stage of plasticity of BMC (Fig. 3). In cluster 125, genes involved in the regulation of liver fibrosis such as *MMP2* and *MMP9* were pointed out. These results were consistent with liver fibrosis recovered by BMC transplantation. *MMP9* has been reported to facilitate the induction of hematopoietic cells from the marrow via the kit signal transduction pathway [26]. This result might suggest that ECM might be important for the




Fig. 5. For the genes, the data of microarray (A) and RT-PCR (B) were classified into clusters by SOM, respectively. Clusters with similar elements were arranged close to each other in the matrix.

Table 2
Selected *gene* grouped to clusters

Cluster No.	GenBank ID	Gene description
Clusters with remarkable variation of gene expression in F1		
86	U52951	Enhancer of zeste homolog 2 (EZH2); ENX1H
	X06368 X68932	Macrophage colony-stimulating factor 1 receptor (CSF1R) o-fms proto-oncogene
	Y00864 NM02099	c-kit proto-oncogene
	U14173	ski proto-oncogene
	M92415	Fibroblast growth factor 6 (FGF6)
69	X07439	Homeobox protein 3.1 (HOX3.1)
	X57487	Paired box protein 8 (PAX8)
	U43788	POU domain class 2-associating factor 1 (POU2AF1); OCT-binding factor 1 (OBF1); BOB1; OCA-B
	M84819	Retinoic acid receptor- γ (RXR- γ ; RXRG)
	AF015848	E2F transcription factor 3 (E2F3)
	Z22649	mpl proto-oncogene; thrombopoietin receptor
	L27105	MOESIN-ezin-radin-like protein (MERLIN); schwannomin (SCH); neurofibromatosis 2(NF2)
	U51196	EB1 APC-binding protein
	Y00671	met proto-oncogene
	Z12604	Matrix metalloproteinase 11 (MMP11); stromelysin 3 (STMY3)
70	D90156	Myogenin (MYOG); myoD1-related protein
	U51037	CCCTC-binding factor (CTCF)
	U06119	Cathepsin H
142	J04946	Angiotensin-converting enzyme (ACE); dipeptidyl carboxypeptidase I (DCP1); kinase II
	U10551	Gem induced immediate early protein
	L34290	Transducin β -5 subunit GTP-binding protein G(i)/G(s)/G(t) β subunit 3
	M96653	Adenylate cyclase 6
	Z71173	Inositol 1,4,5-triphosphate receptor 2
	L76946	Phosphodiesterase 1C
	U12919	Adenylate cyclase type VII (AIP pyrophosphate-lyase) (adenylyl cyclase) (KTAA0037)
	D31788	BP3 alloantigen
	AA000715	S100 calcium-binding protein A1; S-100 protein α chain
	U97327	Calcylin binding protein
	U73004	Antileukoproteinase 1 (ALP1); secretory leukocyte protease inhibitor
140	U58992	Mothers against decapentaplegic homolog 1 (MADH1; mSMAD1);
	U36203	TGF- β signaling protein 1
	D17571	snoN; ski-related oncogene
	U68058	NADPH-cytochrome P450 reductase (CPR); POR
	U77638	Secreted frizzled-related protein 3 (SFRP3; mFIZ); frezzled
	M33385	Mothers against dpp homolog 5 (SMAD5; MADH5)
		Neurotrophic tyrosine kinase receptor type 2 (NTRK); tyrosine kinase receptor B (TRKB)
	X57277	ras-related C3 botulinum substrate 1 (RAC1)
	M21531	Calbindin-28K; calbindin 1 (CALB1)
	U53142	Nitric oxide synthase 3, endothelial cell
	U37775	Tuberin: TSC2 (tuberous sclerosis 2 protein)
	J05261	Lysosomal protective protein; cathepsin A; carboxypeptidase C (CPC); MO54
	M81591	Membrane metallo endopeptidase
	M14222	Cathepsin B (CTSB)
	X15475	Peripherin (PRPH)
141	U61969	Wingless-related MMTV integration site 10a protein (WNT10A)
	X76292	Desert hedgehog homolog (DHH); HHG3
	X67962	Interleukin 7 (IL7)
	X66196	Recoverin (RCV1; RCVRN); cancer-associated retinopathy protein (CAR protein), 23-kDa photoreceptor cell-specific protein
	U57311	14-3-3 protein η ; protein kinase C inhibitor protein 1 (KCIP1); tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein η polypeptide (YWHAH)
	X16490	Macrophage plasminogen activator inhibitor 2 (PAI2; PLANH2)
	X05211	Laminin γ 1 subunit (LAMC1); laminin B2 subunit
125	U03421	Interleukin 11 (IL11)
	M84324	Matrix metalloproteinase 2 (MMP2)
	NM008610	
	X72795	Matrix metalloproteinase 9 (MMP9)
	NM013599	
	M59470	Cystatin C; cystatin 3 (CST3)

(continued on next page)

Table 2 (continued)

Cluster No.	GenBank ID	Gene description
143	U94350	Radical fringe homolog (RFNG)
	U37720	Cell division cycle 42 homolog (CDC42); 25-kDa GTP-binding protein (G25K)
	X73985	Calbindin 2 (CALB2); calretinin
	X61432	Calmodulin (CALM; CAM)
	U48853	ork-associated substrate (CRKAS; CAS)
	U24680	Dishevelled 2 homolog (DVL2)
	D00611	Basic immunoglobulin superfamily (BASIGIN; BSG); membrane glycoprotein 42 (GP42), neurothelin; CD147 antigen
92	M28730	Tubulin β 4 (TUBB4)
	Z21848	DNA polymerase δ catalytic subunit (POLD1)
	U37331	T-box protein 6 (TBX6)
	M61909	relA proto-oncogene; NF- κ -B transcription factor p65 subunit (NF- κ B p65)
	U18542	Calcitonin receptor 1b
	U17985	Cannabinoid receptor 1 (CNR1; CBR), brain cannabinoid receptor
	U41285	Segment polarity protein dishevelled homolog 3 (DVL3), DSH homolog 3
	X62622	Tissue inhibitor of metalloproteinase 2 (TIMP2)
	NM011594	
	L07803	Thrombospondin 2 (THBS2; TSP2)
	X53929	Decorin (DCN); bone proteoglycan II (PG-S2), PG40
	X61435	Neuronal kinesin heavy chain (NKHC); KIF5C
	D10061	DNA topoisomerase I (<i>Top1</i>)
	D28492	Caspase 2 (CASP2); NEDD2 protein; ICH1 cysteine protease
	X66323	X-ray repair-complementing defective repair in Chinese hamster cells 5 (XRCS5)
Clusters with remarkable variation of gene expression in F2		
17	AF017085	BAP-135 homolog; DIWSIT; general transcription factor II-1 (GTF2I)
	U77969	Neuronal PAS domain protein 2
	X97817	Semaphorin F (SEMAF)
	M84487	Vascular cell adhesion molecule 1 (VCAM1)
	M59378	Tumor necrosis factor receptor superfamily member 1B2 (TNFRSF1B2); tumor necrosis factor receptor 2 (TNFR2)
	U25995	Receptor (TNFRSF)-interacting serine-threonine protein kinase 1 (RIPK1; RIP)
	L22472	BCL2-associated X protein membrane isoform alpha (BAX-alpha)
	L33406	Uromodulin
	AF007268	Fibroblast growth factor 15 (FGF15)
	AF030433	Dickkopf homolog 1 (mDKK1)
	AF031896	Cerberus-related protein1 (CERR1)
	X58995	Calcium/calmodulin-dependent protein kinase IV catalytic subunit (CAM kinase-CR; CAMKIV;
		CAMKIV;
34	D32132	Hairy and enhancer of split protein 5 (HES5)
	Z93947	Semaphorin H (SEMAH)
	U69535	Semaphorin J (SEMAJ)
	X97818	Semaphorin G (SEMA5B); SEMA5B
	U25416	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8); CD30L receptor
	U39643	fas-associated factor 1 (FAF1)
	Z22703	Fibroblast growth factor 7 (FGF7)
	X63615	Calcium/calmodulin-dependent protein kinase type II β subunit (CAM-kinase II β ; CAMK-II β)
	U43187	Mitogen-activated protein kinase kinase kinase 3 (MAPKKK3; MAP3K3; MAPK/ERK kinase kinase 3 (MEK kinase 3; MEKK3)
	L35236	Mitogen-activated protein kinase 10 (MAP kinase 10 MAPK10; PRKM10); MAP kinase p49 3F12; Stress-activated o-jun N-terminal kinase 3 (JNK3); SAPK/ERK kinase 2 (SERK2)
16	U03856	Receptor-type protein tyrosine phosphatase (PTPRCAP); C polypeptide-associated protein; CD45-Associated protein (C045-AP), LSM
	L20331	Adenosine A3 receptor
	L41145	Bone morphogenetic protein 5 (BMP5)
	AB006787	Mitogen-activated protein kinase kinase kinase 5 (MAPKKK5; MAP3K5); MAPK/ERK kinase kinase S (MEKK5); apoptosis signal-regulating kinase 1 (ASK1)
	U92456	Serine/alanine-rich protein specific kinase 2 (SRPK2), WW domain binding protein 6 (WBP6)
15	X81579	Insulin-like growth factor-binding protein 1 (IGF-binding protein 1; K3FBP1)
	U60530	Mothers against decapentaplegic homolog 2 (MADH2; mSMAD2)
	AB005141	Klotho protein (KL)
	U77039	Four and a half LM domains 1 (FLH1); KyoT
51	Z32675	Hairless protein (HR)
	L10075	DNA-binding protein SMBP2
	S56660	Retinoic acid receptor β (RAR- β ; RARB); nuclear receptor subfamily 1 group B member 2

Table 2 (continued)

Cluster No.	GenBank ID	Gene description
32	X57413	Transforming growth factor β 2 (TGF- β 2; TGF β 2)
	M20473	cAMP-dependent protein kinase type I β regulatory chain (PRKAR1B)
	Y00703	Guanine nucleotide-binding protein alpha stimulating activity polypeptide (GNAS)
	Y07836	Stimulated by retinoic acid protein 14 (STRA14); STRA13; E47 interaction protein 1 (EIP1)
	X85993	Collapsin 1; semaphorin IIIA (SEMA3A), SEMAD
	L28177	Growth arrest and DNA damage-inducible protein (GADD45), DNA damage-inducible transcript 1
	L33768	Janus tyrosine-protein kinase 3 (JAK3)
	U07617	Growth factor receptor-bound protein 2 (GRB2); ASH protein
	L02526	Mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1; MAPKK1; MAP2K1; PRKMK1); MAPK/ERK kinase 1 (MEK1)
	U66058	DNA ligase III; polydeoxyribonucleotide synthase (ATP) (DNL3)
33	L28819	Involucrin (IVL)
	X97052	Mitogen-activated protein kinase kinase 6 (MAP kinase kinase 6: MAPKK6; MAP2K6; PRKMK6); MAPK/ERK kinase 6 (MEK6); SAPKK3
	L09562	Protein-tyrosine phosphatase γ (R-PTP- γ ; PTPRG)
	Z32767	DNA damage repair & recombination protein 52 homolog (RAD52)
14	X81466	Ephrin type A receptor 7 (ephrin A7; EPHA7), embryonic brain receptor tyrosine kinase (EBK); developmental kinase 1 (mDK1)
	U37522	Tumor necrosis factor superfamily member 10 (TNFSF10); TNF-related apoptosis inducing ligand
	D38258	Fibroblast growth factor 9
	X77113	Growth differentiation factor 9 (GDF9)
	X06381	Leukemia inhibitory factor (LIF); cholinergic differentiation factor
	Z22532	Syndecan 1 (SYND1)
	M75716	Alpha-1-antitrypsin, 1-2 (AAT2), serine proteinase inhibitor 1-2 (SPI1-2); alpha 1 protease inhibitor 2; alpha-1- antiproteinase
	M64292	Anti-proliferative B-cell translocation gene 2 (BTG2); NGF- inducible protein TIS21
	L23971	Fragile X mental retardation syndrome 1 homolog (FMR1; FMRP)
13	U95610	NIMA-related protein kinase 2 (NEK2)
	U05252	Special AT-rich sequence-binding protein 1 (SATB1)
	U70017	Cyclin-D binding Myb-like protein (hDMPI)
	AF001287	Neural cell adhesion molecule 2 (NCAM2), olfactory axon cell adhesion molecule (OCAM)
	J04806	Osteopontin (OP); bone sialoprotein 1; minopontin; early T-lymphocyte activation 1 protein (ETA1); secreted phosphoprotein 1 (SPP1), calcium oxalate crystal growth inhibitor protein
	X83930	Cadherin 5 (CDH5); vascular epithelial cadherin (VE-cadherin)
	AF003747	Zinc transporter 4 (ZNT4)
	M16472	Myelin proteolipid protein (PLP). lipophilin; DM20
	XI5830	7B2 neuroendocrine protein: secretogranin V (SGV; SCG5)
	X72307 NM010427	Hepatocyte growth factor (HGF)
	D84372	Non-receptor type II protein cytosome, phosphocytosome phosphatase
	M38700	ATP-dependent DNA helicase II 70-kDa subunit 70-kDa thyroid autoantigen; lupus Ku autoantigen protein p70 CTC box-binding factor 75-kDa subunit (CTCBF; CTCF75)
cluster with remarkable variation of gene expression in F3		
1	UB6441 NM010950	numfaiike (numbL; m-nbl)
	M33158	CD3 antigen zeta (CD3Z)
	X04648	Low-affinity IgG Fc receptor II β (FCGR2B)
	D49658	LIM-homeodomain protein L3; LHX8
	L12705	Engrailed protein (En-2) homolog
	D49474	SRF-box containing gene 17 (SOX17)
	X73573	Homeobox protein D3 (HOXD3)
	NM010468	
	U62522	Sp4 zinc finger transcription factor
	U25096	Lung Kruppel like factor (LKLf)
	X90329	Lbx 1 transcription factor
	X61753	Heat shock factor 1
	U53925	Transcription factor C1
	U97076	FLICE-like inhibitory protein long form (FLIP-L)
18	M55S12	WT1; Wilms tumor protein; tumor suppressor
	M16449	Myeloblastosis proto-oncogene (MYB)
	X13945	Lung carcinoma myc-related oncogene 1 (L-myc; mycL1)
	M26391	Retinoblastoma-associated protein 1 (RB1); phosphoprotein 105 (PP105)
	U65594	Breast cancer type 2 susceptibility protein (BRCA2)
	U04807	FMS-like tyrosine kinase 3 ligand (FLT3L)
	M34563	T-cell-specific surface glycoprotein CD28

(continued on next page)

Table 2 (continued)

Cluster No.	GenBank ID	Gene description
2	M32240 M63801 AF013282 U63386 J05154	Peripheral myelin protein 22 (PMP22); CD25 antigen; SR13 myelin protein Gap junction alpha 1 protein (GJA1), connexin 43 (CXN43; CX43) T-box protein 15 (TBX15); TBX14; TBX8 Early development regulator 1 (EDR1); pdyhomeotic 1 homolog (mPHI) Lecithin cholesterol acyltransferase (LCAT); phosphatidylcholine sterot acyltransferase; phospholipid cholesterol acyltransferase
137	M55171 D50311 X14943 U12570 V00727 U36799 S59388 Z31683 S53216 AF039601 X06203	Rhodopsin (RHO), opsin (mOPS) Myocyte enhancer factor 2B (MEF2B) Contactin 1 (CNTN1); F3 neuronal cell adhesion molecule (F3CAM) von Hippel-Lindau syndrome homolog (VHLH) fos proto-oncogene retinoblastoma- like protein 2 (RSL2); retinoblastoma-related protein PRB2/p130 Erythropoietin receptor (EPOR) activin A receptor type 1B Tyrosine-protein kinase ryk; kinase vik; nyk-R TGF-beta receptor type IB (betaglycan); candidate tumor suppressor gene Interleukin 8 (IL6)
Clusters with remarkable variation of gene expression in F4		
152	L12140 M98502 S79463 X91144 U04294 M14220 NM008155 M95200 NM009505 M30643 U51866 U17112 U67916 U49739	Groucho gene-related protein (GRG); amino enhancer of split protein (AES) Zinc finger protein 46 Semaphorin I (SEMAI) P-selectin glycoprotein ligand 1 (PSGL1; SELPLG; SELP1) Electrocardiographic QT syndrome 2 potassium channel subunit Glucose-6-phosphate isomerase (GPI) Vascular endothelial growth factor (VEGF) Heparin-binding growth factor 5 (HBGF5); fibroblast growth factor 5 (FGF5) Casein kinase II alpha 1 related sequence 4 (CSNK2A1-RS4) Dentin sialophosphoprotein (DSPP) Unconventional myosin VI
153	S663B5 X85994 U28724	CREB-binding protein Semaphorin IIIC (SEMA3C); SEMAE Postmeiotic segregation increased 2 homolog (PMS2)
135	X12875 L24755 X83106 U34960 D86726	Neural cell adhesion molecule LI (N-CAM LI; LtCAM; CAML1) Bone morphogenetic protein 1 (BMP1) MAX dimerization protein (MAD) Transducin beta-2 subunit MCM6 DNA replication licensing factor (P105MCM)
136	D31967 U59496 X85992 X07640 X57796 NM011609 X53798 X78850 U43144 X83536 Y13602	Jumonji protein Hypoxia inducible factor 1 alpha subunit (HIF1-alpha; HIF1A); ARNT-interacting protein Somaphorin C (SEMAC) Cell surface glycoprotein MAC-1 alpha subunit; CR-3 alpha subunit; GD11B antigen; leukocyte adhesion receptor MO1; integrin alpha-M (ITGAM) Tumor necrosis factor receptor 1 (TNFR1) Small inducible cytokine subfamily B member 2 (SCYB2); macrophage inflammatory protein 2 (MIP2) Mitogen activated kinase-activated protein kinase 2 (MAPKAP kinase 2; MAPKAPK2); 60-kDa ribosomal protein S6 kinase polypeptide 1 (RPS6KC1) Phospholipase C beta 3 (PLC-beta 3; PLCB3) Matrix metalloproteinase 14 (MMP14); membrane-type matrix metalloproteinase 1 (MTMMP1) Filensin, beaded filament structural protein in lens 1 (BFSP1)
150	AF033011 D63644 S70632 S70756 S70629 S81932 X75330 U89487 U89489 U36340 U42554 U33626	distal-less homeobox protein 5 (DLX5) Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) T-cell leukemia homeobox 1 (TLX1); homeobox protein 11 (HOX11) distal-less homeobox protein 3 (DLX3) Drosophila NK5 transcription factor-related locus 1 (NKX-5.1), H6 homeobox protein 3 (HMX3) LIM homeobox protein cofactor 1A (CUM1A); CUM1B; LIM domain-binding protein 3 (LDB3) CACCC-box-binding protein basic Kruppel like factor (BKLF); Kruppel-like factor 3 (KLF3) Single-minded 2 (SIM2) Promyelocytic leukemia gene (PML)

Table 2 (continued)

Cluster No.	GenBank ID	Gene description
151	X56135	Prothymosin alpha (PTMA)
	U43512	Dystroglycan 1
	M13071	A-raf proto-oncogene
	M36829	Heat shock 84-kDa protein 1 (HSP84-1); HSP90
	M89802	Wingless-related MMTV integration site 7b protein (WNT7B)
	M30903	B-lymphocyte kinase (BLX)
	U43298	Laminin β 3 subunit (LAMB3); kalinin B1 subunit
	D29015	Hepatic nuclear factor 4-alpha (HNF4-alpha)
	NM008281	
	M31042	Immediate early response protein 2 (IER2); T-lymphocyte activated protein; cyclo-heximide-induced Protein 1 (CHX1)
148	U43900	STAM; signal transducing adaptor molecule
	M13177	Transforming growth factor β 1 (TGF- β 1; TGFB1)
	M30644	Fibroblast growth factor 2 (FGF2)
	NM008006	
	M76601	Cardiac myosin heavy subunit alpha isoform (MYH6; MYHCA)
	AB009453	Transcription factor 21 (TCF21); basic helix-loop-helix factor COR1; POD1
	S71659	LIM homeobox protein 4 (LHX4); GSH4
	S79041	Genomic screened homeobox protein 2 (GSH2)
	U58533	est2 repressor factor (ERF)
	J03770	Homeobox protein D4 (HOXD4); HOX4.2; HOX5.1
149	X59252	Homeobox protein 8 (HOX8)
	J03168	Interferon regulatory factor 2 (IRF2)
	S68108	Brahma-related protein 1 (BRG1); swi/snf-related matrix-associated actin dependent regulator of chromatin subfamily a member 4 (SMARCA4)
	D78382	Transducer of erbB2 (TROB; TOB)
	X59421	Fli-1 ets-related proto-oncogene
	M62860	Myelin protein zero
	D31942	Oncostatin M (OSM)
	M29464	Platelet-derived growth factor A subunit (PDGFA; POGF1)
	M69042	PKC- δ ; protein kinase C δ type
	U29539	Retinoic acid-inducible E3 protein; stimulated by retinoic acid 13 (STRA13), hematopoietic-specific Protein E3; orfB
133	U26967	Cordon-bleu protein (COBL)
	L38248	LIM homeobox protein 3 (LHX3; UM3)
	X56230	Octamer-binding transcription factor 1 (OCT1; OTF1); NF-A1; POU domain class 2 transcription factor 1 (POU2F1)
	X13721	Homeobox protein 2.4 (HOX2.4)
	L04662	γ -Aminobutyric acid transporter 4 (GABA-A transporter 4; GABT4)
	U59746	B-cell lymphoma protein W (BCLW); BCL2-like protein 2 (BCL2L2)
	M16819	Lymphotoxin alpha (LTA), tumor necrosis factor β (TNF- β ; TNFB)
	U12147	Laminin alpha 2 subunit (LAMA2), dystrophin muscularis protein (DV); merosin heavy chain; laminin M subunit
	U22421	Leptin (LEP); obese factor (OB)
	D10329	CD7 antigen
134	D86603	btb and cnc homolog 1 (BACH1)
	U36384	Dermis expressed 1 protein (DERM01)
	M58633	P58/GTA; galactosyl transferase associated protein kinase (cdc2-related protein kinase)
	D83698	Activator of apoptosis harakiri (HRK); neuronal death protein 5 (DP5); BID3
	L08235	Clusterin (CLU); clustrin; apolipoprotein J (APOJ); sulfated glycoprotein 2 (SGP2; mSGP2)
	X07414	DNA excision repair protein ERCC1
	U61155	LIM homeobox protein 2 (LIM2); LHX5
	U20553	p57kip2; cdk-inhibitor kip2 (cyclin-dependent kinase inhibitor 1 B); member of the p21CIP1 Cdk inhibitor family; candidate tumor suppressor gene
	U05671	Adenosine A1 receptor (ADORA1)
	L37663	Acetylcholine receptor alpha 7 neural
118	M97017	Bone morphogenetic protein 8A (BMP8A), osteogenic protein 2 (OPS)
	AF027503	guanylate kinase membrane-associated inverted protein 1 (GUKMI1; MAGI-1)
	M84817	Retinoid X receptor alpha (RXR- α); RXRA)
	J03520	Tissue plasminogen activator (T-plasminogen activator PLAT; TPA)
	X99063	Zyxin(ZYX)
	X14194	Nidogen (NID); entactin (ENT)
119	Y15001	Iroquois-related homeobox protein 3 (IRX3)
	Z23066	Microphthalmia-associated transcription factor (MITF; MI); microphthalmia-related protein
	X73360	Transducin-like enhancer of split protein 3 (TLE3; ESG)

(continued on next page)

Table 2 (continued)

Cluster No.	GenBank ID	Gene description
	U65091	Melanocyte-specific gene 1 (MSG1); Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1)
	X97986	Desmocollin 1A/1B (DSC1)
	U81317	Myelin-associated oligodendrocytic basic protein
	U21050	TNF receptor-associated factor 3 (TRAF3); TRAFAMN; C040 receptor-associated factor 1 (CRAF1)
	D83966	Protein tyrosine phosphatase
	L19622	Tissue inhibitor of metalloproteinase 3 (TIMP3); SUN
	AF021031	DiGeorge syndrome chromosome region 6 protein (DGCR6)

plasticity of BMC. In the *F2* time period, clusters 13, 14, 15, 16, 17, 32, 33, and 51 were dramatically changed. In cluster 13, hepatocyte growth factor (HGF) was discovered. HGF is involved in hepatocyte proliferation [27,28]. HGF might also have an important role in GFP/CCl₄ model. In the *F3* time period, clusters 1, 2, 18, and 137 were focused. NumbL is involved in asymmetric division of nerve precursor cells [29]. The HOXD3 genes encode information important for determining the positional relationships of the antero-posterior axis in embryogenesis [30]. NumbL and HOXD3 might have an important role in regulating the plasticity of BMC. In *F4*, clusters 118, 119, 133, 134, 135, 136, 148, 149, 150, 151, 152, and 153 were found. In this period, genes involved in hepatocyte differentiation and homeostasis, such as GPI and HNF4, were focused [31]. This enzyme is essential for the glycolytic metabolism of hepatocytes. In the GFP/CCl₄ model, the level of albumin in bone marrow-derived hepatocytes increased significantly [12]. The fact that an enzyme such as GPI was induced at this period suggests that, at 4 weeks after BMC transplantation, transplanted BMCs begin to possess some of the metabolic functions of hepatocytes. HNF4- α was also upregulated in *F4* period. HNF4 plays an important role in the metabolic regulation of hepatocytes [32,33]. These results might be related with BMC differentiated into functional hepatocyte at this period in GFP/CCl₄ model. VEGF was also upregulated. VEGF promotes vasculogenesis and liver regeneration [34]. VEGF might also have an important role in accelerating the liver regeneration in GFP/CCl₄ model. Gene involved in inflammation such as TNF-R1 was also pointed out in GFP/CCl₄ model. TNF- α related inflammation signal is important in the generation of hepatoblast [17]. These results also showed that TNF- α related signal might be important for plasticity of BMC in GFP/CCl₄ model.

Here, we analyzed the change of molecular signature after BMC transplantation in GFP/CCl₄ model in mRNA level. Still many precise things are unconfirmed, but we think the information is useful to understand the mechanism of the plasticity of BMC in GFP/CCl₄ model. In the future, we are planning to further analyze the mechanisms.

Acknowledgements: We thank Dr. Masaru Okabe (Genome Research Center, Osaka University) for the gift of GFP transgenic mice and Mr. Jun Oba for valuable technical support.

References

- [1] Alison, M.R. et al. (2000) *Nature* 406, 257.
- [2] Petersen, B.E. et al. (1999) *Science* 284, 1168–1170.
- [3] Theise, N.D., Nimmakayalu, M., Gardner, R., Illei, P.B., Morgan, G., Teperman, L., Henegariu, O. and Krause, D.S. (2000) *Hepatology* 32, 11–16.
- [4] Terada, N. et al. (2002) *Nature* 416, 542–545.
- [5] Ying, Q.L., Nichols, J., Evans, E.P. and Smith, A.G. (2002) *Nature* 416, 545–548.
- [6] Hakelien, A.M. and Collas, P. (2002) *Cloning Stem Cells* 4, 379–387.
- [7] Krause, D.S., Theise, N.D., Collector, M.I., Henegariu, O., Hwang, S., Gardner, R., Neutzel, S. and Sharkis, S.J. (2001) *Cell* 105, 369–377.
- [8] Ianus, A., Holz, G.G., Theise, N.D. and Hussain, M.A. (2003) *J. Clin. Invest.* 111, 843–850.
- [9] Stamm, C. et al. (2003) *Lancet* 361, 45–46.
- [10] Hamano, K., Li, T.S., Kobayashi, T., Hirata, K., Yano, M., Kohno, M. and Matsuzaki, M. (2002) *Ann. Thorac. Surg.* 73, 1210–1215.
- [11] Terai, S., Yamaoto, N., Omori, K., Sakaida, I. and Okita, K. (2002) *J. Gastroenterol.* 37, 162–163.
- [12] Terai, S. et al. (2003) *J. Biochem. (Tokyo)* 134, 551–558.
- [13] McTaggart, R.A. and Feng, S. (2004) *Hepatology* 39, 1143–1146.
- [14] Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. and Nishimune, Y. (1997) *FEBS Lett.* 407, 313–319.
- [15] Shinoda, K., Mori, S., Ohtsuki, T. and Osawa, Y. (1992) *J. Comp. Neurol.* 322, 360–376.
- [16] Yamamoto, N. et al. (2004) *Biochem. Biophys. Res. Commun.* 313, 1110–1118.
- [17] Watanabe, T. et al. (2002) *Dev. Biol.* 250, 332–347.
- [18] Sakaida, I., Terai, S., Yamamoto, N., Aoyama, K., Ishikawa, T., Nishina, H. and Okita, K. (2004). *Hepatology* (in press).
- [19] Schena, M., Shalon, D., Davis, R.W. and Brown, P.O. (1995) *Science* 270, 467–470.
- [20] Xiao, L., Wang, K., Teng, Y. and Zhang, J. (2003) *FEBS Lett.* 538, 117–124.
- [21] Quaglino, E. et al. (2004) *J. Clin. Invest.* 113, 709–717.
- [22] Ishigaki, S. et al. (2002) *FEBS Lett.* 531, 354–358.
- [23] Nagata, M. et al. (2003) *Int. J. Cancer* 106, 683–689.
- [24] Fujio, K., Evarts, R.P., Hu, Z., Marsden, E.R. and Thorgeirsson, S.S. (1994) *Lab. Invest.* 70, 511–516.
- [25] Zaret, K.S. (2000) *Mech. Dev.* 92, 83–88.
- [26] Heissig, B. et al. (2002) *Cell* 109, 625–637.
- [27] Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimonishi, M., Sugimura, A., Tashiro, K. and Shimizu, S. (1989) *Nature* 342, 440–443.
- [28] Miyazawa, K. et al. (1989) *Biochem. Biophys. Res. Commun.* 163, 967–973.
- [29] Zhong, W., Feder, J.N., Jiang, M.M., Jan, L.Y. and Jan, Y.N. (1996) *Neuron* 17, 43–53.
- [30] McGinnis, W. (1994) *Genetics* 137, 607–611.
- [31] Massillon, D., Arinze, I.J., Xu, C. and Bone, F. (2003) *J. Biol. Chem.* 278, 40694–40701.
- [32] Li, J., Ning, G. and Duncan, S.A. (2000) *Genes Dev.* 14, 464–474.
- [33] Kamiya, A., Inoue, Y. and Gonzalez, F.J. (2003) *Hepatology* 37, 1375–1384.
- [34] Redaelli, C.A., Semela, D., Carrick, F.E., Ledermann, M., Candinas, D., Sauter, B. and Dufour, J.F. (2004) *J. Hepatol.* 40, 305–312.